Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 121-130 of 429 for multiple

Edit search filters
  1. A Study to Compare the Effectiveness and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. A Study to Evaluate Daratumumab in Treating Transplant-Eligible Participants with Multiple Myeloma

    Jacksonville, FL

  3. Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma

    Rochester, MN

  4. First In Human (FIH) Study of REGN5459 in Patients With Relapsed or Refractory Multiple Myeloma (MM)

    Rochester, MN

  5. A Study to Evaluate ION251 to Treat Patients with Relapsed/Refractory Multiple Myleoma

    Scottsdale/Phoenix, AZ, Rochester, MN, Jacksonville, FL

  6. Study of ISB 1342, a CD38/​CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

    Rochester, MN

  7. Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants with Relapsed or Refractory Multiple Myeloma

    Jacksonville, FL

  8. Study to Evaluate Mechanisms of Immunomodulator Sensitivity and Resistance in Multiple Myeloma

    Jacksonville, FL, Rochester, MN, Scottsdale/Phoenix, AZ

  9. A Study Evaluating the Addition of Venetoclax (ABT-199) to Patients with Multiple Myeloma who are Receiving Bortezomib and Dexamethasone as Standard Therapy

    Rochester, MN

  10. A Study Of GC012F (AZD0120), A CAR T Therapy Targeting CD19 And BCMA In Subjects With Relapsed/Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer